Gross, B., Pawlak, M., Lefebvre, P
The goal is to lose fat while maintaining strength, mobility, and metabolic function
Jardiance (empagliflozin) is an SGLT2 inhibitor
Even with statistical adjustments, residual confounding from factors not captured in health records, such as family history of hair loss, lifestyle habits, or precise nutritional status, cannot be fully ruled out
As of March 2025, 11 states cover GLP-1s for weight loss under their state employee health plan, nine states provide coverage under their state Medicaid program, and five states provide coverage under both programs
This page covers what the stack does, how researchers dose it (pre-blend or separate vials), the reconstitution math for common blend ratios, side effects, and how it compares to CagriSema